查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608108

感染疾病疫苗市場：依產品、感染疾病和最終用戶 - 全球預測 2025-2030

Infectious Vaccines Market by Product (Preventive Vaccine, Therapeutic Vaccine), Infectious Disease (Allergy, Cervical Cancer, DTP), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年感染疾病疫苗市場估值為300.1億美元，預計2024年將達318.3億美元，複合年成長率為8.98%，到2030年將達到548.3億美元。

感染疾病疫苗是透過刺激人體免疫反應，提供針對各種感染疾病的免疫力的生技藥品。對感染疾病疫苗的需求至關重要，因為它們在預防疾病爆發、降低發病率和死亡率以及實現群體免疫方面發揮著重要作用。這些疫苗的應用涵蓋針對流感、肝炎、麻疹和 COVID-19 等疾病的公共衛生計劃、個人化免疫接種和全球健康舉措。最終用途包括政府衛生部門、醫院、診所和研究機構，所有這些機構都將疫苗用於大規模免疫宣傳活動和個人化預防護理。影響感染疾病疫苗市場的關鍵成長要素包括預防醫學意識的提高、疫苗開發的技術進步、政府的免疫措施以及對疫苗研究的大力資助。新興市場開拓的驅動力是新疫苗的開發，例如基於mRNA的疫苗和多效價疫苗，它們在大流行期間和針對快速變異的病毒具有潛力。公司可以透過投資研究並與政府和非政府組織建立合作夥伴關係來擴大疫苗分銷網路，從而利用這些機會。然而，市場面臨著可能阻礙其成長的限制和挑戰，例如高昂的研發成本、嚴格的法律規範和疫苗猶豫不決。促進成長的創新領域包括個人化疫苗、減少低溫運輸挑戰的耐熱疫苗以及提高易用性的無針輸送系統。市場洞察也指出，疫苗分發和監測將轉向數位平台，這可以最佳化供應鏈和接種後後續工作。市場動態是動態和競爭的，需要不斷創新並適應不斷變化的公共衛生環境和新出現的疾病。

主要市場統計
基準年[2023] 300.1億美元
預測年份 [2024] 318.3億美元
預測年份 [2030] 548.3億美元
複合年成長率（%） 8.98%

市場動態：揭示快速發展的感染疾病疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變感染疾病疫苗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 愛滋病毒、癌症和糖尿病等慢性病盛行率高
    • 控制流行病的政府優先活動
    • 提高消費者的健康意識和支出
  • 市場限制因素
    • 疫苗生產高成本、工期長
  • 市場機會
    • 公共和私人研發投資的增加
    • 採用新型感染疾病疫苗
  • 市場問題
    • 疫苗的潛在副作用和不利事件

波特五力：引領感染疾病疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解感染疾病疫苗市場的外部影響

外部宏觀環境因素對感染疾病疫苗市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解感染疾病疫苗市場競爭狀況

感染疾病疫苗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣：感染疾病疫苗市場供應商績效評估

FPNV定位矩陣是評估感染疾病疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製感染疾病疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，感染疾病疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 愛滋病毒、癌症和糖尿病等慢性病的盛行率很高
      • 控制傳染病的政府優先活動
      • 提高消費者的健康意識和支出
    • 抑制因素
      • 疫苗生產成本高、週期長
    • 機會
      • 增加公營和私營部門對研發的投資
      • 採用新型感染疾病疫苗
    • 任務
      • 疫苗的潛在副作用和不利事件
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章感染疾病疫苗市場：依產品

  • 介紹
  • 預防性疫苗
  • 治療性疫苗

第7章感染疾病疫苗市場：依感染疾病

  • 介紹
  • 過敏
  • 子宮頸癌
  • DTP
  • 肝炎
  • 流感
  • 腦膜炎奈瑟菌
  • MMR
  • 肺炎球菌
  • 脊髓灰質炎
  • 輪狀病毒
  • 水痘

第8章感染疾病疫苗市場：依最終用戶分類

  • 介紹
  • 成人
  • 兒科的

第9章 北美、南美感染疾病疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太感染疾病疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲感染疾病疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat BIoTech
  • Biological E Ltd.
  • CSL Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Vaccine, Ltd.
  • Johnson and Johnson Services Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd
  • Sinovac BIoTech Ltd.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market was valued at USD 30.01 billion in 2023, expected to reach USD 31.83 billion in 2024, and is projected to grow at a CAGR of 8.98%, to USD 54.83 billion by 2030.

Infectious vaccines are biological preparations that provide immunity against various infectious diseases by stimulating the body's immune response. The necessity for infectious vaccines is paramount due to their critical role in preventing disease outbreaks, reducing morbidity and mortality, and achieving herd immunity. The application of these vaccines spans public health programs, individual immunizations, and global health initiatives targeting diseases such as influenza, hepatitis, measles, and COVID-19. The end-use scope includes government healthcare departments, hospitals, clinics, and research institutions, all of which utilize vaccines for mass immunization campaigns and individual preventive care. Key growth factors influencing the infectious vaccines market include increasing awareness of preventive healthcare, technological advancements in vaccine development, government initiatives for immunization, and the robust funding for vaccine research. Emerging opportunities in the market are driven by the development of novel vaccines, such as mRNA-based vaccines and multi-valent vaccines, which offer potential during pandemics or against rapidly mutating viruses. Companies can capitalize on these opportunities by investing in research and securing partnerships with governmental and non-governmental organizations to expand vaccine distribution networks. However, the market faces limitations and challenges such as high R&D costs, stringent regulatory frameworks, and vaccine hesitancy among populations, which can inhibit market growth. Innovative areas for growth include personalized vaccines, thermostable vaccines that mitigate cold chain challenges, and needle-free delivery systems that enhance ease of use. Market insights also indicate a shift towards digital platforms for vaccine distribution and monitoring, which can optimize supply chains and post-vaccination follow-ups. The nature of the infectious vaccines market is dynamic and highly competitive, necessitating continuous innovation and adaptation to changing public health environments and emerging diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 30.01 billion
Estimated Year [2024] USD 31.83 billion
Forecast Year [2030] USD 54.83 billion
CAGR (%) 8.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Vaccines Market

The Infectious Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic diseases including HIV, cancer, diabetes
    • Government focused activities to control epidemic diseases
    • Rising consumer awareness and expenditure regarding health
  • Market Restraints
    • High costs and longer timelines required for vaccine production
  • Market Opportunities
    • Growing investment by public & private sector for R&D endeavors
    • Introduction of novel infectious vaccines
  • Market Challenges
    • Possibilities of vaccine side effects and adverse events

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Vaccines Market

A detailed market share analysis in the Infectious Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Vaccines Market

A strategic analysis of the Infectious Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech, Biological E Ltd., CSL Limited, DAIICHI SANKYO COMPANY, LIMITED, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Vaccine, Ltd., Johnson and Johnson Services Inc., Lonza Group AG, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Novavax, Inc., Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt., Ltd, and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Preventive Vaccine and Therapeutic Vaccine.
  • Based on Infectious Disease, market is studied across Allergy, Cervical Cancer, DTP, Hepatitis, Influenza, Meningococcal, MMR, Pneumococcal, Polio, Rotavirus, and Varicella.
  • Based on End User, market is studied across Adults and Pediatrics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic diseases including HIV, cancer, diabetes
      • 5.1.1.2. Government focused activities to control epidemic diseases
      • 5.1.1.3. Rising consumer awareness and expenditure regarding health
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and longer timelines required for vaccine production
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing investment by public & private sector for R&D endeavors
      • 5.1.3.2. Introduction of novel infectious vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Possibilities of vaccine side effects and adverse events
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Infectious Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Preventive Vaccine
  • 6.3. Therapeutic Vaccine

7. Infectious Vaccines Market, by Infectious Disease

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Cervical Cancer
  • 7.4. DTP
  • 7.5. Hepatitis
  • 7.6. Influenza
  • 7.7. Meningococcal
  • 7.8. MMR
  • 7.9. Pneumococcal
  • 7.10. Polio
  • 7.11. Rotavirus
  • 7.12. Varicella

8. Infectious Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Pediatrics

9. Americas Infectious Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Infectious Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Infectious Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma, Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech
  • 6. Biological E Ltd.
  • 7. CSL Limited
  • 8. DAIICHI SANKYO COMPANY, LIMITED
  • 9. Emergent BioSolutions Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Incepta Vaccine, Ltd.
  • 12. Johnson and Johnson Services Inc.
  • 13. Lonza Group AG
  • 14. Merck & Co., Inc.
  • 15. Mitsubishi Tanabe Pharma Corporation
  • 16. Novartis International AG
  • 17. Novavax, Inc.
  • 18. Pfizer, Inc.
  • 19. Sanofi SA
  • 20. Serum Institute of India Pvt., Ltd
  • 21. Sinovac Biotech Ltd.

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023